骨髓纤维化
医学
预测模型
鲁索利替尼
内科学
肿瘤科
血液肿瘤
生存分析
真性红细胞增多症
国际预后积分系统
总体生存率
骨髓
骨髓增生异常综合症
癌症
作者
Francesco Passamonti,Francisco Cervantes,Alessandro M. Vannucchi,Enrica Morra,Elisa Rumi,Arturo Pereira,Paola Guglielmelli,Ester Pungolino,Marianna Caramella,Margherita Maffioli,Cristiana Pascutto,Mario Lazzarino,Mario Cazzola,Ayalew Tefferi
出处
期刊:Blood
[American Society of Hematology]
日期:2009-12-15
卷期号:115 (9): 1703-1708
被引量:884
标识
DOI:10.1182/blood-2009-09-245837
摘要
Age older than 65 years, hemoglobin level lower than 100 g/L (10 g/dL), white blood cell count greater than 25 x 10(9)/L, peripheral blood blasts 1% or higher, and constitutional symptoms have been shown to predict poor survival in primary myelofibrosis (PMF) at diagnosis. To investigate whether the acquisition of these factors during follow-up predicts survival, we studied 525 PMF patients regularly followed. All 5 variables had a significant impact on survival when analyzed as time-dependent covariates in a multivariate Cox proportional hazard model and were included in 2 separate models, 1 for all patients (Dynamic International Prognostic Scoring System [DIPSS]) and 1 for patients younger than 65 years (age-adjusted DIPSS). Risk factors were assigned score values based on hazard ratios (HRs). Risk categories were low, intermediate-1, intermediate-2, and high in both models. Survival was estimated by the HR. When shifting to the next risk category, the HR was 4.13 for low risk, 4.61 for intermediate-1, and 2.54 for intermediate-2 according to DIPSS; 3.97 for low risk, 2.84 for intermediate-1, and 1.81 for intermediate-2 according to the age-adjusted DIPSS. The novelty of these models is the prognostic assessment of patients with PMF anytime during their clinical course, which may be useful for treatment decision-making.
科研通智能强力驱动
Strongly Powered by AbleSci AI